BioNTech, Shuwen Ink Chinese Distribution Deal for Breast Cancer Stratification Test | GenomeWeb

NEW YORK (GenomeWeb) – Germany's BioNTech Diagnostics and Shuwen Biotech said today that they have signed a deal to commercialize BioNTech's molecular breast cancer stratification test MammaTyper in China.

According to BioNTech, MammaTyper is a CE-IVD marked test that measures expression levels of four genes in breast cancer tissue via RT-qPCR in order to stratify tumor samples into four subtypes: luminal A-like, luminal B-like/HER2 negative, luminal B-like/HER2 positive, HER2 positive/non-luminal, and triple-negative/ductal.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.